**FOI Ref: 6413**

**Category(ies): Clinical - Drugs**

**Subject: Usage of Somatropins**

**Date Received: 01/06/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I am researching the usage of somatropins within the NHS, and would greatly appreciate if you could answer the questions below:    |
| 1. How many patients have you treated in the last 12 months with the following drugs?
* Genotropin
* Humatrope
* Norditropin
* Nutropin
* Omnitrope
* Saizen
* Zomacton
* Any other Somatropin (please specify)
 | * Genotropin – not stocked
* Humatrope – not stocked
* Norditropin – not stocked
* Nutropin – zero patients
* Omnitrope – \*<5 patients
* Saizen – \*<5 patients
* Zomacton – not stocked
 |
| 1. Please provide the number of patients under the age 16 that were treated in the last 12 months with each of the following drugs:
* Genotropin
* Humatrope
* Norditropin
* Nutropin
* Omnitrope
* Saizen
* Zomacton
 | * Genotropin – not stocked
* Humatrope – not stocked
* Norditropin – not stocked
* Nutropin – zero patients
* Omnitrope – \*<5 patients
* Saizen – \*<5 patients
* Zomacton – not stocked
 |

**\*Less than 5 (in figures) <5**

The Trust considers that information you have requested would in some instances where very low volumes exist, clearly identify an individual and constitutes sensitive personal information. It is therefore exempt under section 40 (2) of the Freedom of Information Act and will not be released as this will likely contravene the 1st (used fairly, lawfully and transparently) and 6th (handled in a way that ensures appropriate security, including protection against unlawful or unauthorised processing, access, loss destruction or damage) data protection principles. Also, Data Protection Act Principle 1 state that when processing sensitive personal information, at least one of the conditions in Schedule 3 is met. The section 40 exemption is an absolute exemption and as such no public interest test should be applied.